Originally receiving SBIR support as BIO Pharmaceuticals Inc, Genaissance Pharmaceuticals, Inc. reflects the extensive movement within the biotech space. In 2005 Genaissance was acquired by Clinical Data Inc which was itself acquired by Allergan which became part of the complex international transaction that involved Pfizer and the new entity Actavis, Plc. With close ties to Yale, the firm Genaissance Pharmaceuticals, Inc. was involved in developing personalized medicines through the integration of pharmacogenomics into drug development and marketing. The Company developed a combination of technologies and expertise, called HAP Technology, which allows population genomics to be integrated into the development, marketing and prescribing of new and existing medicines. The key components of the HAP Technology are a database of highly informative, proprietary measures of genomic variation, or haplotypes; a proprietary informatics system, which is called DECOGEN; a process for measuring genomic variation in clinical DNA samples, and clinical genetics development skills.